- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.11. | Merck advances Winrevair in subset of heart failure patients | ||
| 18.11. | FDA takes issue with AstraZeneca TV ad, citing 'misleading impression' of Farxiga indications | ||
| 18.11. | Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor | ||
| 17.11. | Cytokinetics steps into Bristol Myers' shoes, funding heart registry ahead of commercial clash | ||
| 17.11. | After delay, Sandoz's biosimilar Tyruko launches in US to pressure Biogen's blockbuster MS med Tysabri | ||
| 17.11. | Novo unveils newly reduced self-pay prices for Wegovy, Ozempic after White House deal | ||
| 17.11. | Trump relents on Swiss tariffs, knocking rate on pharmaceuticals and other goods down to 15% | ||
| 17.11. | Jazz's HER2 drug Ziihera chalks up another win with 'practice changing' phase 3 result | ||
| 14.11. | FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths | ||
| 14.11. | Otsuka's HAE med Dawnzera, Lilly's oral SERD Inluriyo among drugs scoring EU endorsements | ||
| 14.11. | LB Pharmaceuticals, Celldex hire commercial chiefs as launch plans ramp up | ||
| 14.11. | Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod | ||
| 14.11. | Survey reveals 'cardiology deserts' at heart of Amgen-backed campaign | ||
| 14.11. | Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid | ||
| 14.11. | Biopharma industry gathers momentum in Q3 | ||
| 14.11. | Fierce Pharma Asia-Pfizer's PD-1xVEGF trials; ivonescimab's 1st survival win; Lilly's deal spree | ||
| 13.11. | Bavarian Nordic board chair exits in aftermath of failed private equity takeover | ||
| 13.11. | Lilly, Novo shoot down claims of DTC obesity drug partnership with Mangoceuticals | ||
| 13.11. | Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval | ||
| 13.11. | Boryung breaks ground on penicillin plant expansion in South Korea | ||
| 13.11. | Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings | ||
| 12.11. | Recall roundup: Fresenius, Sun and Teva among drugmakers pulling products in recent weeks | ||
| 12.11. | Lundbeck, Otsuka back survey uncovering 'blind spot' around Alzheimer's agitation | ||
| 12.11. | As pharma sales stagnate, Bayer exec stands firm behind newer meds and latest launch Lynkuet | ||
| 12.11. | J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .